1. Study to determine the effects of doses of relacatib on the metabolism of acetaminophen, ibuprofen and atorvastatin. 2006. https://www.clinicaltrials.gov/ct2/show/NCT00411190?term=relacatib&rank=1 . Accessed 15 June 2015
2. Data from pivotal phase 3 fracture outcomes study for odanacatib, an investigational oral, once-weekly treatment for osteoporosis. 2014. http://www.mercknewsroom.com/news-release/research-and-development-news/merck-announces-data-pivotal-phase-3-fracture-outcomes-st . Accessed 15 June 2015
3. Adami S, Supronik J, Haha T, Brown JP, Garnero P, Haemmerle S.Ortmann CE, Bousset F, TrechelU (2006) Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis. J Bone Miner Res, 21(suppl 1)
4. Amin S, Kopperdhal DL, Melton LJ III, Achenbach SJ, Therneau TM, Riggs BL, Keaveny TM, Khosla S (2011) Association of hip strength estimates by finite-element analysis with fractures in women and men. J Bone Miner Res 26(1):1593–1600
5. Anderson MS, Gendrano IN, Liu C, Jeffers S, Mahon C, Mehta A, Mostoller K, Zajic S, Morris D, Lee J, Stoch SA (2014) Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women. J Clin Endocrinol Metab 99(1):552–560